natgillin/translations-raw huggingface dataset:
Aranesp bruges til at behandle symptomatisk blodmangel hos voksne cancerpatienter med ikke- myeloid malignitet som er i kemoterapi.
Aranesp is used to treat symptomatic anaemia in adult cancer patients with non-bone marrow cancers (non-myeloid malignancies) who are receiving chemotherapy.
Aranesp er blevet undersøgt hos patienter med kronisk nyresvigt i fire undersøgelser af over 1 200 patienter, hvor det blev sammenlignet med rekombinant humant erythropoietin.
Aranesp has been studied in patients with chronic renal failure in four studies involving over 1,200 patients, in which it was compared with recombinant human erythropoietin.
Aranesp er desuden blevet sammenlignet med placebo (en virkningsløs behandling) i to undersøgelser af 669 patienter, som modtog kemoterapi til behandling af cancerformer såsom lungecancer, myelomer eller lymfomer.
Aranesp has also been compared with placebo (a dummy treatment) in two studies involving 669 patients receiving chemotherapy for cancer such as lung cancer, myeloma or lymphoma.
Aranesp er desuden blevet undersøgt hos 124 børn med kronisk nyresvigt for at kontrollere, hvorvidt det absorberes på samme måde som hos voksne.
Aranesp has also been studied in 124 children with chronic renal failure to check that it is absorbed in the same way as in adults.
Aranesp er en er en injektionsvæske, opløsning, der leveres i hætteglas, fyldte sprøjter eller fyldte injektionspenne.
Aranesp is a solution for injection in a vial, a pre-filled syringe or a pre-filled pen.
Aranesp er en klar, farveløs eller svagt perlemorsfarvet opløsning i et hætteglas.
Aranesp is a clear, colourless or slightly pearly solution for injection in vial.
Aranesp findes i forskellige styrker fra 25 til 500 mikrogram/ml.
Aranesp exists in various strengths, from 25 to 500 micrograms per millilitre.
Aranesp gives som en injektion i vævet lige under huden (subkutan injektion).
Aranesp is given as an injection into the tissue just under the skin (subcutaneous injection).
Aranesp kan indsprøjtes af patienten selv eller af omsorgsgiveren, hvis de er behørigt instrueret heri.
Aranesp can be injected by the patient or their carer if they have been trained appropriately.
Aranesp må ikke gives til personer, der er overfølsomme (allergiske) over for darbepoetin alfa eller andre af indholdsstofferne.
Aranesp must not be used in people who are hypersensitive (allergic) to darbepoetin alfa or any of the other ingredients.
Aranesp påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Aranesp has no or negligible influence on the ability to drive and use machines.
Aranesp skal indgives enten subkutant eller intravenøst for at øge hæmoglobinkoncentrationen til maksimalt 12 g/dl (7,5 mmol/l).
Aranesp should be administered either subcutaneously or intravenously in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l).
Aranesp SureClick fyldt pen – Læs indlægsseddel før brug
Aranesp SureClick Pre-filled pen - Read package leaflet before use
Aranesp var lige så effektivt som rekombinant humant erythropoietin til at øge hæmoglobinniveauet hos patienter med kronisk nyresvigt og til at fastholde dette niveau, efter at det var bedret, både når det blev givet som injektion i en vene eller under huden.
Aranesp was as effective as human recombinant erythropoietin at increasing the haemoglobin levels in patients with chronic renal failure, and at keeping these levels maintained after they had been improved, whether given as an injection into a vein or under the skin.
Arava 10 mg filmovertrukket tablet
Arava 10 mg film-coated tablets
Arava 10 mg filmovertrukket tablet leflunomid.
Arava 10 mg film-coated tablets leflunomide
Arava 10 mg filmovertrukne tabletter leflunomid.
Arava 10 mg film-coated tablets leflunomide
Arava 100 mg filmovertrukket tablet
Arava 100 mg film-coated tablets
Arava 20 mg filmovertrukket tablet
Arava 20 mg film-coated tablets
Arava 20 mg filmovertrukne tabletter leflunomid.
Arava 20 mg film-coated tablets leflunomide
Arava anbefales ikke til børn og unge under 18 år.
Arava is not recommended for use in children and adolescents below 18 years of age.
arcoidose (en sygdom karakteriseret ved længerevarende feber, vægttab, ledsmerte og - opsvulmen, hudskader og hævede kirtler), vaskulitis.
arcoidosis (a disease characterised by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands), vasculitis.
Ardannels e
Scarring
Ardannelse
Scarring
ardannelse i nyren, hvilket kan forringe nyrefunktionen
Scarring in the kidney that may reduce kidney function
ardannelse og fortykkelse i lungerne sammen med stakåndethed (lungefibrose)
pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath)
Ardannelse på bindehinden (det beskyttende lag over det hvide i øjet) med beskadigelse, hvor den forbindes til indersiden af øjenlågene (fornix-forkortelse).
Scarring of the conjunctiva (the protective layer over the white of your eye) with damage where it joins to the inside of the eyelids (fornix shortening)
Ardannelse på påføringsstedet
Application site scarring
ARDS er ikke almindeligt hos kræftpatienter.
ARDS is uncommon in patients with cancer;
ARDS forekommer med hyppigheden ’ikke almindelig’ hos patienter med kræft,
ARDS is uncommon in patients with cancer;
Areal under kurven (AUC0-∞)
Area under the curve (AUC0-∞)
Areal under kurven: 587,88 ± 1,63 (% x timer)
Area under the curve: 587.88 ± 1.63 (% x h)
Arealet under kurven (AUC) øgedes omtrent proportionalt med dosis.
Area under the curve increased approximately in proportion to the increase in dose.
Arealet under plasmakoncentrationskurven (AUC) af ertapenem hos voksne øges næsten dosisproportionelt inden for dosisspændet 0,5 - 2 g.
Area under the plasma concentration curve (AUC) of ertapenem in adults increases nearly dose- proportionally over the 0.5 to 2 g dose range.
Arepanrix (H1N1) n = 164)
Arepanrix (H1N1)
Arepanrix er en vaccine, der beskytter mod "pandemisk" influenza.
Arepanrix is a vaccine to protect against ‘pandemic’ flu.
Arepanrix indeholder en influenzastamme kaldet A/California/7/2009 (H1N1)v- lignende stamme (X-179A).
Arepanrix contains a flu strain called A/California/7/2009 (H1N1) v-like strain (X-179A).
Arepanrix suspension og emulsion til injektionsvæske, emulsion
Arepanrix suspension and emulsion for emulsion for injection
Arepanrix suspension og emulsion til injektionsvæske, emulsion.
Arepanrix suspension and emulsion for emulsion for injection
Arepanrix suspension og emulsion til injektionsvæske, emulsion.
Arepanrix suspension and emulsion for emulsion for injection.
aRespondere blev defineret som patienter, der 1) oplevede et ≥ 30 % fald i VAS-score sammenlignet med basislinien; 2) fik stabile eller nedsatte samtidige opioide analgetika; og 3) hvis de fik opiater før infusionen, blev de ved med at få samme type opiater.
aResponders were defined as those patients who 1) experienced a ≥ 30% drop in VASPI score compared to baseline; 2) had stable or decreased concomitant opioid analgesics; and 3) had opiate type unchanged from preinfusion if receiving opiates.
aRespondere blev defineret som patienter, der 1) oplevede et ≥ 30 % fald i VAS-score sammenlignet med basislinien; 2) fik stabile eller nedsatte samtidige opioide analgetika; og 3) hvis de fik opiater før infusionen, blev de ved med at få samme type opiater. b164 patienter afgav VAS-score for ziconotid ved slutningen af titreringen.
aResponders were defined as those patients who 1) experienced a ≥ 30% drop in VASPI score compared to baseline; 2) had stable or decreased concomitant opioid analgesics; and 3) had opiate type unchanged from preinfusion if receiving opiates. b164 patients provided VASPI scores for ziconotide at the end of titration.
aRespondere blev defineret som patienter, der oplevede et ≥ 30 % fald i VAS-score sammenlignet med basislinien.
aResponders were defined as those who experienced a ≥ 30% drop in VASPI score compared to baseline.
Arginin, natriumacetat (E262), natriumchlorid, polysorbat 80 (E433), dinatriumedetat (E386), saltsyre (E507), vand til injektionsvæsker.
Arginine, sodium acetate (E262), sodium chloride, polysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507), water for injections.
Argininhydrochlorid
Arginine hydrochloride
argininosuccinic aciduria
argininosuccinic aciduria;
ARICLAIM 30 mg findes i blisterpakninger med 7, 28 og 98 kapsler.
ARICLAIM 30 mg is available in packs of 7, 28 and 98 capsules.
ARICLAIM 30 mg hårde enterokapsler ARICLAIM 60 mg hårde enterokapsler Duloxetin (som hydrochlorid)
ARICLAIM 30 mg hard gastro-resistant capsules ARICLAIM 60 mg hard gastro-resistant capsules Duloxetine (as hydrochloride)
ARICLAIM 30 mg hårde enterokapsler Duloxetin
ARICLAIM 30 mg hard gastro-resistant capsules Duloxetine
ARICLAIM 30 mg hårde enterokapsler.
ARICLAIM 30 mg hard gastro-resistant capsules
ARICLAIM 60 mg findes i blisterpakning med 28 og 98 kapsler.
ARICLAIM 60 mg is available in packs of 28 and 98 capsules.
ARICLAIM 60 mg hårde enterokapsler
ARICLAIM 60 mg hard gastro-resistant capsules
ARICLAIM 60 mg hårde enterokapsler Duloxetin
ARICLAIM 60 mg hard gastro-resistant capsules Duloxetine
ARICLAIM bør ikke bruges til behandling af børn og unge under 18 år.
ARICLAIM should not be used in the treatment of children and adolescents under the age of 18 years.
ARICLAIM er en hård enterokapsel.
ARICLAIM is a hard gastro-resistant capsule.
Ariclaim kan medføre bivirkninger, som du måske ikke er opmærksom på, f.eks. forhøjede leverenzymer eller forhøjede værdier af kalium, kreatinkinase, sukker eller kolesterol i blodet
Ariclaim may cause effects that you may not be aware of, such as increases in liver enzymes or blood levels of potassium, creatine phosphokinase, sugar, or cholesterol
ARICLAIM kan tages med og uden mad.
ARICLAIM may be taken with or without food.
ARIP 10-30 mg: p-værdi 0,9920
ARIP 10-30 mg: p value 0.9920
ARIP IMD 50/25 mg: p-værdi < 0,0001
ARIP IMD 50/25 mg: p value < 0.0001
Aripiprazol 10 mg (n=27)
Aripiprazole 10 mg (n=27)
Aripiprazol 10 mg (n=37)
Aripiprazole 10 mg (n=37)
Aripiprazol 10 mg (n=44)
Aripiprazole 10 mg (n=44)
Aripiprazol 10 mg (n=48)
Aripiprazole 10 mg (n=48)
Aripiprazol 30 mg (n=25)
Aripiprazole 30 mg (n=25)
Aripiprazol 30 mg (n=30)
Aripiprazole 30 mg (n=30)
Aripiprazol 30 mg (n=48)
Aripiprazole 30 mg (n=48)
Aripiprazol 30 mg (n=51)
Aripiprazole 30 mg (n=51)
Aripiprazol 5-15 mg N=114
Aripiprazole 5-15 mg N=114
Aripiprazol blev undersøgt hos patienter i aldersgruppen 6 til 17 år i to 8-ugers, placebokontrollerede forsøg [én fleksibel dosis (2-15 mg/dag) og én fast dosis (5, 10 eller 15 mg/dag)] og i et 52-ugers åbent forsøg.
Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible- dose (2-15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week open-label trial.
Aripiprazol blev undersøgt hos patienter i aldersgruppen 6 til 17 år i to 8-ugers, placebokontrollerede forsøg [én fleksibel dosis (2-15 mg/dag) og én fast dosis (5, 10 eller 15 mg/dag)] og i et 52-ugers åbent forsøg.
Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2-15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week open-label trial.
Aripiprazol blev undersøgt i et 30-ugers placebokontrolleret forsøg med 296 børn og unge (10-17 år), som opfyldte DSM-IV-kriterierne for maniske eller blandede episoder af bipolær lidelse type 1 med eller uden psykotiske træk, og som havde Y-MRS-score på ≥ 20 ved baseline.
Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10- 17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥ 20 at baseline.
Aripiprazol blev undersøgt i et 30-ugers placebokontrolleret forsøg med 296 børn og unge (10-17 år), som opfyldte DSM-IV-kriterierne for maniske eller blandede episoder af bipolær lidelse type 1 med eller uden psykotiske træk, og som havde Y-MRS-score på  20 ved baseline.
Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score  20 at baseline.
Aripiprazol blev undersøgt i et 30-ugers placebokontrolleret forsøg med 296 børn og unge (10-17 år), som opfyldte DSM-IV-kriterierne for maniske eller blandede episoder af bipolær lidelse type 1 med eller uden psykotiske træk, og som havde Y-MRS-score på 20 ved baseline.
Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score  20 at baseline.
Aripiprazol bør anvendes med forsigtighed til patienter med kendt kardiovaskulær sygdom (myokardieinfarkt eller iskæmisk hjertesygdom i anamnesen, hjertesvigt eller ledningsforstyrrelser), cerebrovaskulær sygdom, tilstande, som disponerer for hypotension (dehydrering, hypovolæmi og behandling med antihypertensiva), eller hypertension, accelereret såvel som malign.
Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.
Aripiprazol er ikke indiceret til behandling af demensrelateret psykose.
Aripiprazole is not indicated for the treatment of dementia-related psychosis.
Aripiprazol er, baseret på resultater fra en fuld skala af standard-genotoksicitetstest, ikke fundet at være genotoksisk.
Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non- genotoxic.
Aripiprazol fordeles i stor udstrækning, med et faktisk fordelingsvolumen på 4,9 l/kg, indikerende omfattende ekstravaskulær fordeling.
Based on results from trials with oral administration of aripiprazole, aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution.
Aripiprazol har høj bindingsaffinitet in vitro for dopamin D2- og D3-, serotonin 5-HT1A- og 5-HT2A- receptorer og moderat affinitet for dopamin D4-, serotonin 5-HT2C- og 5-HT7-, alfa 1-adrenerge og histamin H1- receptorer.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors and moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprazol har høj bindingsaffinitet in vitro for dopamin D2- og D3-, serotonin 5-HT1a- og 5-HT2a- receptorer og moderat affinitet for dopamin D4-, serotonin 5-HT2c- og 5-HT7-, alfa 1-adrenerge og histamin H1- receptorer.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5HT1a and 5HT2a receptors and moderate affinity for dopamine D4, serotonin 5HT2c and 5HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprazol menes at virke hovedsagelig som ”partiel agonist” for receptorerne for neurotransmitterne 5-hydroxytryptamin og dopamin (også kaldet serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Aripiprazol menes hovedsagelig at virke ved delvis stimulation (dvs. som en "partiel agonist") af receptorerne for neurotransmitterne dopamin og 5- hydroxytryptamin (også kaldet serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5- hydroxytryptamine (also called serotonin).
Aripiprazol menes hovedsagelig at virke ved delvis stimulation (dvs. som en "partiel agonist") på receptorerne for neurotransmitterne dopamin og 5- hydroxytryptamin (også kaldet serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ at the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Aripiprazol menes hovedsagelig at virke ved delvis stimulation (dvs. som en “partiel agonist”) af receptorerne for neurotransmitterne dopamin og 5-hydroxytryptamin (også kaldet serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5- hydroxytryptamine (also called serotonin).
Aripiprazol menes hovedsagelig at virke ved delvis stimulation (som en såkaldt “partiel agonist”) af receptorerne for neurotransmitterne dopamin og 5- hydroxytryptamin (også kaldet serotonin).
Aripiprazole is thought to act mainly by being a ‘partial agonist’ for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Aripiprazol metaboliseres via flere enzymsystemer, der involverer CYP2D6- og CYP3A4-enzymer, men ikke CYP1A-enzymer.
Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes, but not CYP1A enzymes.
Aripiprazol og andre antipsykotika bør anvendes med forsigtighed hos patienter med risiko for aspirationspneumoni.
Aripiprazole and other antipsychotic active substances should be used cautiously in patients at risk for aspiration pneumonia.
Aripiprazol og andre antipsykotiske aktive stoffer bør anvendes med forsigtighed hos patienter med risiko for aspirationspneumoni.
Aripiprazole and other antipsychotic active substances should be used cautiously in patients at risk for aspiration pneumonia.
Aripiprazol-depotinjektion 50 mg/25 mg blev inkluderet som en lavdosis-aripiprazol for at teste analysesensitiviteten, for så vidt angår noninferioritetsdesignet.
The aripiprazole Long-Acting Injectable 50 mg/25 mg dose was included as a low dose aripiprazole to test assay sensitivity for the non-inferiority design.
Aripiprazole
(Invented) name
Aripiprazole -dosis bør halveres ved samtidig administration af Aripiprazole og quinidin.
Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs.
Aripiprazole -gruppen havde en forbedring på 14,97 på TTS-YGTSS-skalaen fra baseline til uge 10; til sammenligning var forbedringen i placebogruppen på 9,62.
Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.
Aripiprazole absorberes godt, med maksimal plasmakoncentration inden for 3-5 timer efter administration.
Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours after dosing.
Aripiprazole Accord 10 mg tabletter aripiprazol
Aripiprazole Accord 10 mg tablets aripiprazole
Aripiprazole Accord 15 mg tabletter aripiprazol
Aripiprazole Accord 15 mg tablets aripiprazole
Aripiprazole Accord 30 mg tabletter aripiprazol
Aripiprazole Accord 30 mg tablets aripiprazole
Aripiprazole Accord 5 mg tabletter aripiprazol
Aripiprazole Accord 5 mg tablets aripiprazole
Aripiprazole Accord 5/10/15 mg tabletter fås i HDPE-flaske med PPCRC-lukning indeholdende 30 eller 100 tabletter.
Aripiprazole Accord 5/10/15 mg tablets are also available in HDPE bottle with PPCRC closure containing 30 or 100 tablets.
Aripiprazole Accord 5/10/15/30 mg tabletter fås i perforeret aluminium/aluminium-enkeltdosisblister i pakningsstørrelser med 14 x 1, 28 x 1, 49 x 1, 56 x 1 eller 98 x 1 tabletter.
Aripiprazole Accord 5/10/15/30 mg tablets are available in Aluminium/Aluminium perforated unit dose blister in pack-sizes of 14x1, 28x1, 49x1, 56x1 or 98x1 tablet.
Aripiprazole Accord anvendes til patienter over 15 år bipolar lidelse type I, en psykisk sygdom med skiftende episoder med abnormt højt humør (maniske episoder) og perioder med normalt humør.
Aripiprazole Accord is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Aripiprazole Accord er effektiv i dosisområdet 10-30 mg/dag.
Aripiprazole Accord is effective in a dose range of 10 to 30 mg/day.
Aripiprazole Accord er til oral anvendelse.
Aripiprazole Accord is for oral use.
Aripiprazole blev også undersøgt i et placebokontrolleret, langvarigt vedligeholdelsesstudie.
Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial.
Aripiprazole blev undersøgt hos patienter i aldersgruppen 6 til 17 år i to 8-ugers, placebokontrollerede forsøg [én fleksibel dosis (2-15 mg/dag) og én fast dosis (5, 10 eller 15 mg/dag)] og i et 52-ugers åbent forsøg.
Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2-15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week open-label trial.
Aripiprazole blev undersøgt i et 30-ugers placebokontrolleret forsøg med 296 børn og unge (10-17 år), som opfyldte DSM-IV-kriterierne for maniske eller blandede episoder af bipolær lidelse type 1 med eller uden psykotiske træk, og som havde Y-MRS-score på ≥ 20 ved baseline.
Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score ≥ 20 at baseline.
Aripiprazole bør anvendes med forsigtighed til patienter med kendt kardiovaskulær sygdom (anamnestisk myokardieinfarkt eller iskæmisk hjertesygdom, hjertesvigt eller ledningsforstyrrelser), cerebrovaskulær sygdom, tilstande som disponerer for hypotension (dehydrering, hypovolæmi og behandling med antihypertensive lægemidler) eller hypertension, accelereret såvel som malign.
Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant.
Aripiprazole er effektivt i et dosisinterval på 10 til 30 mg/dag.
Aripiprazole is effective in a dose range of 10 to 30 mg/day.
Aripiprazole er effektivt til at opretholde klinisk forbedring under fortsættelsesbehandling hos voksne patienter med respons på den indledende behandling.
Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response.
Aripiprazole er ikke indiceret til behandling af demensrelateret psykose.
Aripiprazole is not indicated for the treatment of dementia-related psychosis.
Aripiprazole er, baseret på resultater fra en fuld skala af standard-genotoksicitetstest, ikke fundet at være genotoksisk.
Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non- genotoxic.
Aripiprazole fordeles i stor udstrækning, med et faktisk fordelingsvolumen på 4,9 l/kg, indikerende omfattende ekstravaskulær fordeling.
Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution.
Aripiprazole gennemgår minimal præ-systemisk metabolisme.
Aripiprazole undergoes minimal pre-systemic metabolism.
Aripiprazole har høj bindingsaffinitet in vitro for dopamin D2- og D3-, serotonin 5-HT1a- og 5-HT2a- receptorer og moderat affinitet for dopamin D4-, serotonin 5-HT2c- og 5-HT7-, alfa 1-adrenerge og histamin H1- receptorer.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5HT1a and 5HT2a receptors and moderate affinity for dopamine D4, serotonin 5HT2c and 5HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprazole har i reproduktionstoksicitetsforsøg ikke påvirket fertiliteten.
Aripiprazole did not impair fertility in reproductive toxicity studies.